Omeros Corporation (3O8.F)

3,2180 -0,0080 (-0,25%) Börsenschluss: 09:55PM CEST

Omeros Corporation

The Omeros Building
201 Elliott Avenue West
Seattle, WA 98119
United States
206 676 5000
https://www.omeros.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 198

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Gregory A. Demopulos M.D.	Co-Founder, Chairman, CEO & President	5,53M	N/A	1959
Mr. Michael A. Jacobsen	Chief Accounting Officer, VP of Finance & Treasurer	568,43k	N/A	1958
Mr. Peter B. Cancelmo J.D.	VP, General Counsel & Corporate Secretary	567,19k	N/A	1979
Dr. Pamela Pierce Palmer M.D., Ph.D.	Co-Founder	N/A	N/A	1963
Dr. George A. Gaitanaris M.D., Ph.D.	Chief Scientific Officer & VP of Science	N/A	N/A	1957
Mr. Peter W. Williams	Vice President of Human Resources	N/A	N/A	1968
Dr. Catherine A. Melfi Ph.D.	Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems	N/A	N/A	1959
Ms. Nadia Dac	VP & Chief Commercial Officer	N/A	N/A	1970
Dr. Andreas Grauer M.D.	VP & Chief Medical Officer	N/A	N/A	1961

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Corporate Governance

Omeros Corporations ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 8, Vorstand: 9, Shareholderrechte: 5, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.